Assessment of clinical outcomes of medicinal cannabis therapy for depression: Analysis from the UK Medical Cannabis Registry.
Sajed MangooSimon ErridgeCarl HolveyRoss CoomberDaniela A Riano BarrosUrmila BhoskarGracia MwimbaKavita PraveenChris SymeonSimmi Sachdeva-MohanJames J RuckerMikael Hans SodergrenPublished in: Expert review of neurotherapeutics (2022)
CBMP treatment was associated with reductions in depression severity at 1, 3, and 6 months. Limitations of the study design mean that a causal relationship cannot be proven. This analysis provides insights for further study within clinical trial settings.